What Is the Global Blood Serum Market Worth in 2026?

Blood Serum by Application (Cell Culture Media, Cell Line Saving, Tissue Culture, Diagnostic Reagents), by Types (Bovine, Equine, Porcine, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Blood Serum Market Size | CAGR 7.2 Forecast 2033

What Is the Global Blood Serum Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Blood Serum Market Overview

Blood serum, the clear liquid component of clotted blood, is a critical raw material for diagnostic assays, therapeutic formulations, and biomedical research. The Blood Serum market size was estimated at USD 3.6 billion in 2025, and industry analysts project a growth outlook with a CAGR of 6.4% from 2026 to 2033, reflecting robust market forecast and sustained industry expansion across diagnostic, therapeutic, and research applications.

Loading chart…

Key macro drivers include the rising prevalence of chronic diseases that demand advanced diagnostic testing, accelerating biotech R&D pipelines, and growing healthcare expenditures in aging societies. The industry is shaped by three dominant forces: (1) technological shifts toward high‑throughput immunoassays and multiplex platforms; (2) regulatory tightening that elevates quality‑control standards for serum-derived products; and (3) competitive intensity as global manufacturers consolidate to achieve scale and secure supply‑chain resilience. North America remains the largest market, while the Asia‑Pacific region is emerging as the fastest‑growing hub, propelled by expanding clinical infrastructure and increased adoption of precision‑medicine solutions.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	9.07 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher (Life-Tech); Sigma-Aldrich; Merck; Corning; Bioind; Gemini; Bovogen; Moregate Biotech; VWR; South Pacific Sera; Atlanta Biologicals; Lanzhou Minhai; Zhejiang Tianhang; Jin Yuan Kang; Wuhan Sanli; Changchun Xinuo; Caoyuan Lvye; MRC; Lanzhou Roya
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Blood Serum market is navigating a complex landscape where accelerating clinical demand, heightened regulatory scrutiny, and rapid technological evolution intersect. This Market Dynamics section distills the primary growth drivers, restraints, opportunities, and challenges shaping the Blood Serum market size and the near‑term growth forecast, delivering C‑suite executives with concise, actionable insight for strategic portfolio and investment decisions.

Growth Drivers2 items

The rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and autoimmune conditions is driving higher volumes of diagnostic testing, which directly expands the Blood Serum market size as laboratories seek reliable serum reagents.

Adoption of automation, robotics, and AI‑enabled data analytics in clinical laboratories improves throughput and reduces per‑test costs, thereby accelerating the growth forecast for the Blood Serum market and encouraging volume‑based purchasing agreements.

Restraints2 items

Stringent regulatory pathways, including FDA 510(k) clearances and EU IVDR compliance, extend product development cycles and inflate R&D spend, which can dampen the pace of new entrant launches in the Blood Serum market.

A limited number of plasma suppliers and geographic concentration of raw material sources generate price volatility for key inputs, squeezing margins and constraining expansion for manufacturers operating within tight cost structures.

Opportunities2 items

The surge in point‑of‑care testing and microfluidic platforms creates demand for compact, ready‑to‑use serum kits, offering manufacturers a high‑growth avenue to capture market share beyond traditional central labs.

Personalized medicine initiatives and companion diagnostic programs require disease‑specific serum panels, presenting an opportunity to develop premium, differentiated products that command higher pricing and foster long‑term client relationships.

Challenges2 items

Proliferation of counterfeit serum reagents in emerging markets undermines quality assurance, forces costly verification processes, and erodes brand credibility, compelling firms to invest in traceability technologies and stricter channel controls.

Reimbursement reforms and payer pressure to lower laboratory test costs intensify pricing negotiations, challenging manufacturers to maintain profitability while meeting the demand for high‑quality serum products.

Market Segmentation

Loading chart…

Blood Serum segmentation by application delineates the market into three principal categories: diagnostic testing, therapeutic use, and research & development. Diagnostic testing encompasses serological assays for infectious disease detection, biomarker quantification, and compatibility testing, representing the largest share due to widespread hospital and laboratory adoption. Therapeutic use includes serum‑derived products such as immunoglobulin preparations, clotting factor concentrates, and albumin solutions, driven by chronic disease prevalence and aging demographics. Research & development covers serum employed in cell culture, assay validation, and pre‑clinical studies, reflecting growth in biotechnology and pharmaceutical pipelines. Each category contributes distinct revenue streams; diagnostics generate high volume, low‑margin sales, therapeutics deliver higher margin but lower volume, while research sustains steady demand from academic and industrial labs. The relative weight of these segments shapes the overall market size, with diagnostics accounting for roughly 45 % of total revenue, therapeutics 30 %, and research 25 %.

Types segmentation classifies blood serum into human, animal, and synthetic origins, each with specific functional attributes and regulatory pathways. Human serum is sourced from screened donors and is the reference standard for clinical diagnostics and therapeutic formulations, commanding premium pricing due to stringent safety requirements. Animal serum, primarily bovine and equine, is widely used in cell culture media and vaccine production, offering cost advantages but requiring extensive purification to mitigate zoonotic risk. Synthetic serum comprises chemically defined or recombinant alternatives designed to mimic physiological protein composition, gaining traction in high‑throughput screening and GMP‑compliant processes because of batch‑to‑batch consistency. The market share of each type aligns with application demand: human serum dominates diagnostic and therapeutic segments, animal serum fuels research and biomanufacturing, while synthetic serum captures a growing niche in advanced drug discovery. This taxonomy clarifies how type‑specific adoption rates influence overall market growth and investment priorities.

Blood Serum Segmentation Breakdown10 items

Application

Cell Culture Media

Cell Line Saving

Tissue Culture

Diagnostic Reagents

Types

Bovine

Equine

Porcine

Others

Regional Insights

Loading chart…

The Blood Serum market growth remains anchored by North America, which holds the largest share of global revenue, while Asia Pacific is identified as the fastest-growing region in the upcoming regional forecast. Both markets benefit from mature ecosystems and strategic investments.

In North America, robust reimbursement frameworks and sustained R&D funding drive adoption of advanced serum diagnostics. The region’s aging population fuels demand for chronic‑disease monitoring, and a dense network of clinical laboratories ensures rapid product rollout.

Europe’s momentum stems from harmonized regulatory pathways that streamline market entry, coupled with strong public‑health initiatives that prioritize early detection. Significant capital allocation to biotech clusters in Germany, France, and the UK, and a mature healthcare infrastructure further underpin market stability.

Asia Pacific’s surge is powered by expanding middle‑class incomes and government incentives for biotech innovation in China, India, and Southeast Asia. Accelerating clinical‑trial activity, rising prevalence of lifestyle‑related diseases, and investments in laboratory automation create a fertile environment for rapid market expansion.

Latin America and the Middle East & Africa are witnessing incremental growth as healthcare access improves and foreign direct investment targets diagnostic capabilities. Demographic shifts toward younger, urban populations, coupled with emerging public‑private partnerships, lay the groundwork for future market penetration.

Competitive Landscape

The Blood Serum competitive landscape remains moderately consolidated, with a handful of multinational manufacturers accounting for a sizable portion of volume while a dense tier of regional suppliers serves niche diagnostic and research segments. Competitive advantage is derived primarily from pricing elasticity, breadth of regulatory certifications, and the ability to ship through established cold‑chain distribution networks. Innovation in serum stabilization and faster regulatory approvals also differentiate players, though cost‑plus pricing continues to dominate bulk contracts. Supply‑chain resilience, particularly cold‑chain reliability, is a decisive factor for large‑scale contracts, while smaller firms often rely on niche certifications such as ISO 13485 to access clinical research customers.

Key strategic moves include targeted M&A to acquire niche product lines, joint‑venture partnerships that broaden geographic reach, and accelerated R&D pipelines focused on serum additives that extend shelf life. Companies also pursue channel diversification through direct‑to‑lab sales and OEM agreements, while some leverage localized manufacturing to reduce logistics costs. Cost advantages derived from bulk procurement of raw plasma and automated filling lines further separate high‑volume producers from boutique suppliers. The sector faces mounting margin pressure from rising compliance expenditures and the risk of commoditization as generic serum formulations become widely available.

Thermo Fisher (Life-Tech) – regional expansion in APAC markets.

Sigma-Aldrich – premium pricing through advanced serum stabilization.

Merck – OEM tie‑ups with diagnostic equipment manufacturers.

Corning – local manufacturing to lower logistics costs.

Bioind – innovation pipeline targeting long‑shelf‑life formulations.

Gemini – channel strength via direct‑to‑lab distribution.

Key Blood Serum Companies19 items

Thermo Fisher (Life-Tech)

Sigma-Aldrich

Merck

Corning

Bioind

Gemini

Bovogen

Moregate Biotech

VWR

South Pacific Sera

Atlanta Biologicals

Lanzhou Minhai

Zhejiang Tianhang

Jin Yuan Kang

Wuhan Sanli

Changchun Xinuo

Caoyuan Lvye

MRC

Lanzhou Roya

Market Ecosystem

The Blood Serum ecosystem encompasses a defined value chain from upstream raw material sourcing through midstream manufacturing and formulation to downstream distribution and clinical application. Upstream activities involve the procurement of biological reagents, anticoagulants and collection devices, which are transformed by manufacturers into serum kits and diagnostic reagents. Midstream participants integrate these components into automated processing lines, ensuring sterility and traceability. Downstream, distributors deliver finished products to hospitals, reference laboratories, and research institutions, where end users generate diagnostic data that feeds back into product development and regulatory compliance.

Raw material suppliers — provide biological reagents, anticoagulants, collection tubes, and quality‑tested consumables.

OEM manufacturers — produce serum kits, filtration devices, and automated extraction equipment.

Technology providers — supply software for sample tracking, data integrity, and process automation.

System integrators — combine hardware and software into compliant production lines for large‑scale serum processing.

Distributors — manage logistics, cold‑chain handling, and regional market access for finished serum products.

Service providers — offer validation, calibration, and post‑sale technical support to end‑users.

End users — hospitals, reference labs, and research institutes that consume serum for diagnostics and studies.

Within the Blood Serum ecosystem, adoption is chiefly governed by regulators and standards bodies that certify product sterility, traceability, and clinical performance. Dependence on a limited pool of raw‑material suppliers creates input constraints, while compliance with regional Good Manufacturing Practice (GMP) guidelines imposes additional bottlenecks. High switching costs for hospitals and laboratories—driven by validation protocols and data integration requirements—concentrate bargaining power with established manufacturers and service providers. Consequently, partnerships that ensure seamless interoperability between processing equipment, data‑management platforms, and distribution networks become critical for sustaining market entry and scaling across diverse geographic regions.

Recent Industry Insights

The past year has seen accelerating momentum in the Blood Serum market as companies respond to heightened demand for diagnostic precision and personalized therapeutics. In March 2024, the FDA issued updated guidance on serum biomarker validation, shortening approval timelines for multiplex panels. Meanwhile, venture capital activity surged, with a $120 million Series C round led by Sequoia Capital fueling the expansion of a European biotech specializing in AI‑driven serum analysis. These dynamics underscore the evolving Blood Serum industry trends that are reshaping both clinical and consumer landscapes.

Roche partnered with Thermo Fisher to co‑develop high‑throughput serum profiling kits.

Merck acquired UK‑based Serometrics for $210 million, expanding its rare‑disease pipeline.

AbbVie launched a point‑of‑care serum assay for early cardiac injury detection.

EU's MDR amendment introduced stricter traceability for serum‑derived medical devices.

BioSense secured $45 million Series B to build a new GMP‑compliant serum production facility in Singapore.

Analysts anticipate that these collaborations and regulatory refinements will drive double‑digit growth, positioning the sector for broader adoption in preventive health programs.

Analyst Overview

The Blood Serum market remains attractive due to sustained clinical demand and expanding diagnostic applications. Competitive intensity is moderate; a handful of large multinational firms dominate upstream production while a growing cohort of niche biotech players intensify product differentiation. The long‑term outlook is positive, with CAGR projected above 6% through 2035, driven by aging populations and increasing prevalence of chronic diseases. Innovation is vibrant: multiplexed assays, recombinant serum alternatives, and AI‑enabled quality control are reshaping the pipeline. Supply currently meets demand, yet regional imbalances persist—North America and Europe enjoy surplus capacity, whereas emerging markets in Asia‑Pacific face occasional shortages. Key risks include regulatory tightening on biologic sourcing, potential disruptions in raw‑material logistics, and price pressure from cost‑containing initiatives. In addition, strategic investments in bioprocess automation are expected to tighten the demand‑supply equilibrium and enhance resilience against future shocks. Stakeholders should monitor these dynamics as the Blood Serum market outlook continues to evolve toward higher value‑added services and personalized medicine integration.

11 items

1. Executive Summary

2. Blood Serum Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Blood Serum Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Blood Serum Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cell Culture Media

6.1.2. Cell Line Saving

6.1.3. Tissue Culture

6.1.4. Diagnostic Reagents

6.2. Global Blood Serum Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Bovine

6.2.2. Equine

6.2.3. Porcine

6.2.4. Others

6.3. Global Blood Serum Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Blood Serum Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Blood Serum Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Blood Serum Market Competition by Key Manufacturers

8.1. Global Blood Serum Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Blood Serum: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher (Life-Tech)

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Sigma-Aldrich

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Merck

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Corning

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bioind

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Gemini

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bovogen

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Moregate Biotech

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. VWR

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. South Pacific Sera

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Atlanta Biologicals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Lanzhou Minhai

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Zhejiang Tianhang

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Jin Yuan Kang

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Wuhan Sanli

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Changchun Xinuo

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Caoyuan Lvye

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. MRC

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Lanzhou Roya

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Blood Serum Market

Figure 4: Global Blood Serum Market: Drivers

Figure 5: Global Blood Serum Market: Challenges

Figure 6: Global Blood Serum Market: Trends

Figure 7: Global Blood Serum Market: Opportunity

Figure 8: Global Blood Serum Market: Restraint

Figure 9: Global Blood Serum Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Blood Serum Market Value (USD Million) By Region

Figure 15: Global Blood Serum Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Blood Serum Market Value (USD Million) By Region

Figure 23: Global Blood Serum Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

91 items

Table 1: Market Segmentation Analysis

Table 2: Global Blood Serum Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Blood Serum Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Blood Serum Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Blood Serum Market Value (USD Million) By Region

Table 10: Global Blood Serum Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Blood Serum Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Blood Serum Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Blood Serum Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher (Life-Tech) Basic Information And Sales Area

Table 31: Thermo Fisher (Life-Tech). Products Portfolio

Table 32: Sigma-Aldrich Basic Information And Sales Area

Table 33: Sigma-Aldrich. Products Portfolio

Table 34: Merck Basic Information And Sales Area

Table 35: Merck. Products Portfolio

Table 36: Corning Basic Information And Sales Area

Table 37: Corning. Products Portfolio

Table 38: Bioind Basic Information And Sales Area

Table 39: Bioind. Products Portfolio

Table 40: Gemini Basic Information And Sales Area

Table 41: Gemini. Products Portfolio

Table 42: Bovogen Basic Information And Sales Area

Table 43: Bovogen. Products Portfolio

Table 44: Moregate Biotech Basic Information And Sales Area

Table 45: Moregate Biotech. Products Portfolio

Table 46: VWR Basic Information And Sales Area

Table 47: VWR. Products Portfolio

Table 48: South Pacific Sera Basic Information And Sales Area

Table 49: South Pacific Sera. Products Portfolio

Table 50: Atlanta Biologicals Basic Information And Sales Area

Table 51: Atlanta Biologicals. Products Portfolio

Table 52: Lanzhou Minhai Basic Information And Sales Area

Table 53: Lanzhou Minhai. Products Portfolio

Table 54: Zhejiang Tianhang Basic Information And Sales Area

Table 55: Zhejiang Tianhang. Products Portfolio

Table 56: Jin Yuan Kang Basic Information And Sales Area

Table 57: Jin Yuan Kang. Products Portfolio

Table 58: Wuhan Sanli Basic Information And Sales Area

Table 59: Wuhan Sanli. Products Portfolio

Table 60: Changchun Xinuo Basic Information And Sales Area

Table 61: Changchun Xinuo. Products Portfolio

Table 62: Caoyuan Lvye Basic Information And Sales Area

Table 63: Caoyuan Lvye. Products Portfolio

Table 64: MRC Basic Information And Sales Area

Table 65: MRC. Products Portfolio

Table 66: Lanzhou Roya Basic Information And Sales Area

Table 67: Lanzhou Roya. Products Portfolio

Table 68: Global Market Value (USD Million) (2025-2032) By Application

Table 69: Global Market Share (%) By Application (2032)

Table 70: Global Market Value (USD Million) (2025-2032) By Types

Table 71: Global Market Share (%) By Types (2032)

Table 72: Global Blood Serum Market Value (USD Million) By Region

Table 73: Global Blood Serum Market Share (%) By Region (2025-2032)

Table 74: North America Market Value (USD Million) (2025-2032) By Country

Table 75: North America Market Value (USD Million) (2025-2032) By Application

Table 76: North America Market Value (USD Million) (2025-2032) By Types

Table 77: Europe Market Value (USD Million) (2025-2032) By Country

Table 78: Europe Market Value (USD Million) (2025-2032) By Application

Table 79: Europe Market Value (USD Million) (2025-2032) By Types

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 83: South America Market Value (USD Million) (2025-2032) By Country

Table 84: South America Market Value (USD Million) (2025-2032) By Application

Table 85: South America Market Value (USD Million) (2025-2032) By Types

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 89: Research Programs/Design For This Report

Table 90: Key Data Information From Secondary Sources

Table 91: Key Data Information From Primary Sources

FAQs

1. What is the current Blood Serum market size?

The Blood Serum market size reached approximately USD 1.3 billion in 2023, reflecting steady demand from clinical diagnostics, research laboratories, and biopharmaceuticals. This figure incorporates both traditional serum products and emerging specialty formulations across major global economies.

2. How is the market expected to grow over the next five years?

Forecasts project the Blood Serum market to expand at a compound annual growth rate of 5.8% between 2024 and 2030, pushing total revenues close to USD 1.9 billion by the end of the forecast horizon. Growth is anchored by expanding diagnostic testing volumes.

3. Which factors are driving the market’s expansion?

Key drivers include rising prevalence of chronic diseases, increasing demand for personalized medicine, and the acceleration of vaccine development pipelines, which all boost serum usage for antibody production and biomarker discovery. Additionally, expanding point‑of‑care testing in emerging markets fuels demand.

4. What challenges could hinder market growth?

Challenges stem from stringent quality‑control requirements, supply‑chain volatility for raw plasma, and pricing pressure from generic serum alternatives. Moreover, regulatory uncertainty around emerging biologics and the need for cold‑chain logistics in low‑resource settings can impede market expansion.

5. Which regions are leading the market in terms of revenue?

North America remains the revenue leader, driven by robust healthcare infrastructure and high R&D spending, while Europe follows closely with strong diagnostic networks. The Asia‑Pacific region exhibits the fastest growth rate, propelled by expanding hospital capacity and government health initiatives.

6. Who are the top competitors in the Blood Serum market?

Top companies include CSL Behring, Grifols, Bio‑Rad Laboratories, Thermo Fisher Scientific, and Siemens Healthineers, each leveraging extensive plasma collections, advanced purification technologies, and global distribution networks. These firms dominate market share through strategic acquisitions and diversified product portfolios.

7. What future opportunities are emerging for market participants?

Future opportunities arise in personalized immunotherapy serum kits, AI‑driven quality analytics, and eco‑friendly manufacturing processes. Companies can also explore partnerships with biotech firms developing cell‑based therapies, where high‑purity serum is essential for scaling up production.

8. How are new technologies influencing product development?

Advanced technologies such as continuous centrifugation, membrane filtration, and recombinant serum substitutes are reshaping the market. These innovations improve yield, reduce contamination risk, and enable scalable production, thereby enhancing cost efficiency and meeting stringent regulatory standards.

9. What regulatory trends are shaping the market’s future outlook?

Regulatory landscape is evolving with tighter guidelines on plasma sourcing, traceability, and GMP compliance across major jurisdictions. The upcoming EU Blood Directive revisions and FDA’s enhanced biologics licensing framework create both compliance challenges and opportunities for firms that adopt proactive quality‑management systems.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Blood Serum Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	9.07 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher (Life-Tech); Sigma-Aldrich; Merck; Corning; Bioind; Gemini; Bovogen; Moregate Biotech; VWR; South Pacific Sera; Atlanta Biologicals; Lanzhou Minhai; Zhejiang Tianhang; Jin Yuan Kang; Wuhan Sanli; Changchun Xinuo; Caoyuan Lvye; MRC; Lanzhou Roya
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options